Sign in to view content

Baseline Characteristics of Patients Maintaining q12 and q16 Dosing With Aflibercept 8 mg vs Patients With Shortened Treatment Intervals Phase 3 PULSAR Post Hoc Analysis

David R. Chow, MD, FRCS(C)

Video
Published 2023

Related

Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies
David M. Brown, MD
Updates from the Field
2021
Episode 146: Journal Club Discussing PIVOT trial, FLUID trial, Timing of Macula-Off RDs
Jayanth Sridhar, MD
Member Podcasts
2018
Intravitreal Aflibercept 8 mg Injection in Patients With Neovascular Age-Related Macular Degeneration: 48-week Results From the Phase 3 PULSAR Trial
Jignesh I Patel, MD FRCOphth
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more